Who is sponsoring NCT02274987?

NCT02274987 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT02274987?

Interventions in NCT02274987: Specialized tumor board recommendation, Standard radiation therapy.

What condition does NCT02274987 study?

NCT02274987 studies Diffuse Intrinsic Pontine Glioma (DIPG).

Is NCT02274987 still recruiting?

NCT02274987 is currently completed. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT02274987

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Profiling for Individualized Treatment Plan for DIPG

Completed NA Last updated 4 November 2022

What this trial tests

NA trial testing Specialized tumor board recommendation in Diffuse Intrinsic Pontine Glioma (DIPG) in 38 participants. Completed in 24 February 2019.

Timeline

16 September 2014

Primary endpoint
19 December 2018

24 February 2019

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	16 September 2014
Primary completion	19 December 2018
Estimated completion	24 February 2019
Sites	5 locations across United States

Drugs / interventions tested

Specialized tumor board recommendation
Standard radiation therapy

Conditions studied

Diffuse Intrinsic Pontine Glioma (DIPG) — all drugs for Diffuse Intrinsic Pontine Glioma (DIPG) →

Sponsor

University of California, San Francisco

Who can join

Under 25, any sex, with Diffuse Intrinsic Pontine Glioma (DIPG). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The current study will use a new treatment approach based on each patient's tumor genomic profiling consisting of whole exome sequencing and RNA sequencing as well as predictive modeling.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.
Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, et al · · 2018 · cited 141× · PMID 30322880 · DOI 10.1158/1078-0432.ccr-18-1345
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
Gupta N, Goumnerova LC, Manley P, Chi SN, et al · · 2018 · cited 86× · PMID 29741745 · DOI 10.1093/neuonc/noy070
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
Przystal JM, Cianciolo Cosentino C, Yadavilli S, Zhang J, et al · · 2022 · cited 84× · PMID 35157764 · DOI 10.1093/neuonc/noac041
OpenPBTA: The Open Pediatric Brain Tumor Atlas.
Shapiro JA, Gaonkar KS, Spielman SJ, Savonen CL, et al · · 2023 · cited 66× · PMID 37492101 · DOI 10.1016/j.xgen.2023.100340
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR, Sundaram RK, Breuer GA, Peng S, et al · · 2019 · cited 61× · PMID 31439867 · DOI 10.1038/s41467-019-11732-6
Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Li D, Bonner ER, Wierzbicki K, Panditharatna E, et al · · 2021 · cited 51× · PMID 33658570 · DOI 10.1038/s41598-021-84513-1
Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.
Azad TD, Jin MC, Bernhardt LJ, Bettegowda C. · · 2020 · cited 50× · PMID 31896079 · DOI 10.3171/2019.9.focus19699
A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG).
Lin GL, Monje M. · · 2017 · cited 47× · PMID 28362421 · DOI 10.3791/55360

Verify or expand the search:

Other trials of Specialized tumor board recommendation

Trials testing the same drug.

NCT03739372 — Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade · NA · active not recruiting

Other recruiting trials for Diffuse Intrinsic Pontine Glioma (DIPG)

Currently open trials in the same condition.

NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02274987 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02274987.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing